Observational studyPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2025
Vaccine immunity in patients with 22q11.2 microdeletion syndrome.
Observational study in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluation of vaccine immunity against tetanus, hepatitis B, measles, mumps, rubella and varicella, in migrant adolescents aged 13 to 18 years arriving in Geneva in 2023.European journal of pediatrics · 2026Observational
- The systemic effects of 22q11.2 deletion syndrome on immunity.Journal of human immunity · 2026Review
- Vaccine immunity in patients with 22q11.2 microdeletion syndrome.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with microdeletion 22q11.2 syndrome (MDS) exhibit immunological defects, characterized by abnormalities in the development of the thymus, which plays a crucial role in T-cell maturation and immune response. As a result, these patients may have impaired adaptive immunity, with decreased responses to vaccination.
methodsThis was a prospective observational study. Vaccine serology (tetanus, diphtheria, Haemophilus influenzae type b for children <5 years, measles, varicella, hepatitis A and B, and SARS-CoV-2) and immune parameters were assessed in MDS patients aged between 1 and 25 years followed in Geneva between February 2022 and April 2023.
results41 MDS patients were included. The median age was 13 years old. Most of them reported recurrent otitis and bronchitis up to 10 years, and a mild COVID-19 disease in the past. Immunological work-up indicated normal immunoglobulin levels and lymphocyte counts for the majority. Most patients were well vaccinated for tetanus, diphtheria, Haemophilus influenzae type b and measles, but only half were fully vaccinated for hepatitis B, and SARS-CoV-2 and only a quarter for hepatitis A. 70% of the patients had received 3 doses of pneumococcal conjugate vaccine in infancy but only a minority an additional dose. While most of them were seroprotected against tetanus, diphtheria, and Hib, a substantial number lacked seroprotection against varicella, measles, hepatitis B, and pneumococcus.
conclusionThis study suggests that regular assessment of antibody levels for measles, hepatitis B, varicella, and pneumococcus, regardless of vaccination status should be encouraged in MDS patients, with reimmunization according to vaccine serology, to enhance vaccine immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.